Skip to main content
  • Saved

Commented on 's Post

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

Source :

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892292/

COVID-19 pandemic has led to an unprecedented need to develop an effective and safe vaccine in a timely manner. SARS-CoV-2 binds to human cells via the spike (S) protein, which targets the cellular angiotensin-converting enzyme (ACE-2) expressed on their surface.

  • 1 week 3 days
    Unfortunately there is limited information on vaccine efficacy or aes in myeloma and other cancers but given the rates of severe illness, adherence to the current guidelines certainly makes sense until more is known